Risk factors and clinical outcomes of encapsulating peritoneal sclerosis: A case–control study from China

医学 腹膜透析 优势比 内科学 连续不卧床腹膜透析 置信区间 单变量分析 腹膜平衡试验 腹膜炎 胃肠病学 外科 多元分析
作者
Miaoqing Lu,Hongjian Ye,Dongni Chen,Chunyan Yi,Jianxiong Lin,Haiping Mao,Xiao Yang,Xueqing Yu,Wei Chen
出处
期刊:Peritoneal Dialysis International [SAGE]
卷期号:42 (5): 505-512 被引量:1
标识
DOI:10.1177/08968608211029224
摘要

Encapsulating peritoneal sclerosis (EPS) is an uncommon, but serious complication in patients with continuous ambulatory peritoneal dialysis (PD) who have a considerable mortality rate. This study aimed to identify risk factors and outcomes of EPS in Chinese patients on PD.Sixteen patients on PD who met the International Society for Peritoneal Dialysis criteria for diagnosis of EPS in the First Affiliated Hospital of Sun Yat-Sen University from 1997 to 2018 were included. Patients without EPS were matched for age, sex and the duration of PD and selected at a 1:3 ratio for the controls. A case-control study was conducted to analyse the clinical profile and risk factors associated with EPS in patients.The prevalence of EPS in patients on PD in our centre was 0.55%. The percentage of EPS significantly increased with the duration of PD. In univariate regression analysis, a history of peritonitis (odds ratios (OR): 2.83; 95% confidence interval (CI): 0.82-9.68; p = 0.08), peritoneal glucose exposure (OR: 1.12; 95% CI: 1.03-1.22; p < 0.01) and a high peritoneal transport status (OR: 14.70; 95% CI: 1.85-117.02; p < 0.01) were associated with EPS in patients on PD. However in the multivariate model, only a high peritoneal transport status (adjusted odds ratios (aOR): 13.65; 95% CI: 1.69-109.96; p = 0.01) was independently associated with EPS.The rate of EPS significantly increases with the duration of PD. Progressive peritoneal dysfunction, especially a high peritoneal transport status, is associated with a higher risk of EPS in this population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
科研通AI5应助Ezio_sunhao采纳,获得10
2秒前
科研通AI5应助笨笨的复天采纳,获得10
3秒前
3秒前
Annie完成签到 ,获得积分10
3秒前
Akim应助ZYY采纳,获得10
3秒前
共享精神应助zfcc采纳,获得10
4秒前
4秒前
dodo发布了新的文献求助10
5秒前
wzy发布了新的文献求助10
5秒前
洁净之卉发布了新的文献求助50
5秒前
康若英完成签到,获得积分10
5秒前
波波完成签到 ,获得积分10
5秒前
健壮的涑发布了新的文献求助10
5秒前
豆豆完成签到 ,获得积分10
6秒前
万能图书馆应助Qwepo8采纳,获得10
6秒前
7秒前
桐桐应助科研通管家采纳,获得10
7秒前
爆米花应助科研通管家采纳,获得30
7秒前
跳跃的翼应助科研通管家采纳,获得10
7秒前
wanci应助科研通管家采纳,获得10
7秒前
Hello应助科研通管家采纳,获得10
7秒前
Jasper应助科研通管家采纳,获得10
7秒前
思源应助科研通管家采纳,获得10
7秒前
wanci应助科研通管家采纳,获得10
7秒前
科研通AI6应助科研通管家采纳,获得10
7秒前
orixero应助科研通管家采纳,获得10
7秒前
7秒前
科研通AI5应助风屿采纳,获得10
7秒前
MchemG应助科研通管家采纳,获得30
7秒前
华仔应助科研通管家采纳,获得10
7秒前
搜集达人应助科研通管家采纳,获得10
8秒前
领导范儿应助科研通管家采纳,获得10
8秒前
脑洞疼应助科研通管家采纳,获得10
8秒前
chen发布了新的文献求助10
8秒前
烟花应助科研通管家采纳,获得10
8秒前
CodeCraft应助科研通管家采纳,获得10
8秒前
科研通AI5应助科研通管家采纳,获得10
8秒前
传奇3应助科研通管家采纳,获得10
8秒前
英俊的铭应助科研通管家采纳,获得10
8秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
LRZ Gitlab附件(3D Matching of TerraSAR-X Derived Ground Control Points to Mobile Mapping Data 附件) 2000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5133034
求助须知:如何正确求助?哪些是违规求助? 4334358
关于积分的说明 13503569
捐赠科研通 4171281
什么是DOI,文献DOI怎么找? 2287061
邀请新用户注册赠送积分活动 1287947
关于科研通互助平台的介绍 1228783